Sematrinity 4Mg Combipack Pre Filled Pen 3Ml With Disposable Hypodermic Needles 4

Sematrinity 4mg Combipack Pre Filled Pen 3ml With Disposable Hypodermic Needles 4 may interact with the following medicines:

• Antidiabetic medicines (e.g., insulin, glimepiride, gliclazide): Taking these medicines together may increase the risk of low blood sugar. Your doctor may adjust the dose and recommend regular blood glucose monitoring.
• Other semaglutide-containing medicines or GLP-1 receptor agonists: Do not use these medicines together unless your doctor specifically recommends the combination.
• Oral medicines: Semaglutide delays gastric emptying, which may delay the absorption of some medicines taken by mouth. Your doctor may recommend additional monitoring if you are taking medicines that require rapid gastrointestinal absorption.
• Warfarin and other coumarin anticoagulants: More frequent INR monitoring may be required when treatment with semaglutide is started.

Sematrinity 4mg Combipack Pre Filled Pen 3ml With Disposable Hypodermic Needles 4 may interact with diseases, including:

• Pancreatitis: Acute pancreatitis has been reported during treatment with semaglutide. Stop using the medicine and seek immediate medical attention if you develop severe, persistent abdominal pain that may radiate to your back, with or without vomiting. Do not restart treatment if pancreatitis is confirmed.
• Diabetic Retinopathy: Patients with a history of diabetic retinopathy should be monitored during treatment, as worsening of diabetic retinopathy has been reported in clinical studies. Inform your doctor if you notice any changes in vision.
• Gallbladder disease: Semaglutide has been associated with gallstones and gallbladder inflammation, particularly during rapid weight loss. Inform your doctor if you develop severe upper abdominal pain, fever, or jaundice.
• Gastroparesis: This medicine slows stomach emptying and may worsen symptoms in people with delayed stomach emptying. Inform your doctor if you have gastroparesis before starting treatment.
• Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia Syndrome Type 2 (MEN 2): This medicine is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2 because of the potential risk of thyroid C-cell tumours observed in animal studies. Patients should report symptoms such as a lump in the neck, persistent hoarseness, difficulty swallowing, or shortness of breath immediately.

Use Sematrinity 4mg Combipack Pre Filled Pen 3ml With Disposable Hypodermic Needles 4 exactly as prescribed by your doctor. It is administered once weekly following the recommended dose-escalation schedule. The dose and duration of treatment depend on your blood sugar control and treatment response. Do not change the dose or stop treatment without consulting your doctor.

Using more than the prescribed dose may cause severe nausea, vomiting, abdominal pain, or low blood sugar when taken with other antidiabetic medicines. Seek immediate medical attention in case of an overdose.

If you miss a dose and the next scheduled dose is more than 48 hours away, administer the missed dose as soon as possible. If less than 48 hours remain before your next scheduled dose, skip the missed dose and administer the next dose on your regular dosing day. Do not administer two doses within 48 hours.